| Title |
Benzodiazepine Use among Older Adults with Chronic Obstructive Pulmonary Disease
|
|---|---|
| Published in |
Drugs & Aging, February 2013
|
| DOI | 10.1007/s40266-013-0056-1 |
| Pubmed ID | |
| Authors |
Nicholas T. Vozoris, Hadas D. Fischer, Xuesong Wang, Geoffrey M. Anderson, Chaim M. Bell, Andrea S. Gershon, Anne L. Stephenson, Sudeep S. Gill, Paula A. Rochon |
| Abstract |
Patients with chronic obstructive pulmonary disease (COPD) may receive benzodiazepines for a variety of reasons, including as treatment for insomnia, as treatment for depression and anxiety, and to help relieve refractory dyspnoea. However, benzodiazepines have been linked to adverse physiological respiratory outcomes in individuals with COPD. The potential adverse respiratory effects of benzodiazepines in COPD may also be heightened in older adults given their altered pharmacokinetics that increase benzodiazepine half-life. There is minimal information on the scope and nature of benzodiazepine use in the older adult COPD population. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 50% |
| New Zealand | 1 | 25% |
| Hungary | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 274 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| South Africa | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 270 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 3% |
| Student > Master | 9 | 3% |
| Student > Bachelor | 8 | 3% |
| Researcher | 6 | 2% |
| Other | 5 | 2% |
| Other | 11 | 4% |
| Unknown | 226 | 82% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 2% |
| Nursing and Health Professions | 5 | 2% |
| Social Sciences | 3 | 1% |
| Computer Science | 2 | <1% |
| Other | 5 | 2% |
| Unknown | 228 | 83% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 February 2017.
All research outputs
#2,589,994
of 22,701,287 outputs
Outputs from Drugs & Aging
#151
of 1,192 outputs
Outputs of similar age
#28,045
of 282,548 outputs
Outputs of similar age from Drugs & Aging
#2
of 22 outputs
Altmetric has tracked 22,701,287 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,192 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,548 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.